AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04307524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment in the form of combined hormonal contraception
Description: patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare
Study NCT01653340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine
Description: http://nevro.com/corporate/system-us
Study NCT04098796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.
Study NCT04098796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
Study NCT00786253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10 mg on demand use
Study NCT00786253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil daily dosing 10 mg
Study NCT03336814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Administration of terlipressine
Study NCT03336814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study NCT03335683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenidase
Description: drug per os twice day for 7 days, or for 10 days
Study NCT03335683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenidase
Description: drug per os twice day for 7 days, or for 10 days
Study NCT00977613 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise counseling
Description: motivational counseling to exercise a minimum 18 metabolic hours per week
Study NCT03678675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
Study NCT04129112 — intervention group
Intervention type: DRUG
Intervention: We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening
Description: Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
Study NCT01141920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low threshold care
Description: Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
Study NCT01141920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stepped-based care
Description: Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
Study NCT03033160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Ring
Study NCT00240968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
Study NCT01297543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human myeloid progenitor cells
Description: Single intravenous injection/infusion
Study NCT01297543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Background therapy
Study NCT04603963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: power breathe
Description: respiratory muscle training 1 time a day with power breathe 3 sets of 10 repetitions
Study NCT03558308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer based cognitive rehabilitation
Description: Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
Study NCT01297543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Background therapy
Study NCT02561546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p53 gene therapy
Description: Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
Study NCT02561546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-catheter embolization
Description: Trans-catheter embolization alone
Study NCT02561546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trans-catheter embolization
Description: Trans-catheter embolization alone
Study NCT01768065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Expiratory Positive Airway Pressure Device
Description: assigned to Nasal Expiratory Positive Airway Pressure arm
Study NCT01768065 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo sham
Study NCT03597191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercises
Description: Participants in the treatment group will be instructed in the spinal stabilization exercises (SSEs), modeled after the spinal stabilization exercise program designed by Hicks et al. (2005). The SSE program targets muscle activation of spinal stabilizers specifically, the transversus abdominus and lumbar multifidus muscles. Each exercise will be progressed by increasing repetitions and hold time.
Study NCT03597191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Participants in the treatment group will be instructed in the spinal stabilization exercises (SSEs), modeled after the spinal stabilization exercise program designed by Hicks et al. (2005). The SSE program targets muscle activation of spinal stabilizers specifically, the transversus abdominus and lumbar multifidus muscles. Each exercise will be progressed by increasing repetitions and hold time.
Study NCT04605653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management Intervention
Description: Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
Study NCT04241822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular exercises combined with body awareness exercises and cognitive therapy
Description: The intervention is group based and is a combination of information/education, vestibular exercises (head movements and gaze stability exercises) body awareness exercises and cognitive therapy
Study NCT04241822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: The intervention consists of different balance exercises using non-immersive virtual reality
Study NCT03097926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long alimentary limb BPD-DS
Description: BPD-DS with a long strict alimentary limb and a 100-cm common channel.
Study NCT03097926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long alimentary limb BPD-DS
Description: BPD-DS with a long strict alimentary limb and a 100-cm common channel.
Study NCT00328588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: IV
Study NCT00662311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT00662311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00662311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00811980 — intervention group
Intervention type: DRUG
Intervention: Linezolid or Vancomycin
Description: Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
Study NCT00576524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITD
Description: ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
Study NCT00576524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
Study NCT01944644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Low Field Magnetic Stimulation
Description: Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
Study NCT01944644 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low Field Magnetic Stimulation
Description: Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
Study NCT03558308 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham computerized gaming
Description: Sham training with generally stimulating computer-games
Study NCT00615784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
Study NCT02957656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 pLAIV
Description: 10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
Study NCT02957656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 pIIV
Description: Administered by intramuscular injection in the deltoid.
Study NCT02957656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03 adjuvant
Description: Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
Study NCT02072564 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
Study NCT00128557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)
Description: Single dose of 15,000 ug retinol equivalents at or near birth vs a placebo
Study NCT00128557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)
Description: Single dose of 15,000 ug retinol equivalents at or near birth vs a placebo
Study NCT00805298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 32 mg before surgery, 16 mg twice daily the day after surgery
Study NCT00805298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two tablets before surgery, one tablet twice daily on the day after surgery
Study NCT00805298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xyloplyin adrenalin
Description: lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
Study NCT00805298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marcain adrenalin
Description: bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
Study NCT03272256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM156
Description: Sequential 3+3 design.
Study NCT02028936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape juice R@isol
Study NCT02028936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially-available grape juice
Study NCT04458077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discover Learning (SEIL)
Description: This mobile-phone-based intervention will assess the effectiveness of 10 SEIL sessions conducted at the household level with VYAs. Activities were designed to be done individually, with siblings/peers, and with parents/caregivers. This intervention will look at how household composition and types of practice that can enhance SEIL learning.
Study NCT02523456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
Study NCT02523456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Introduce EWS
Description: An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
Study NCT00119613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00119613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: darbepoetin alfa
Study NCT00767507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Study NCT00767507 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
Study NCT00000359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver (Epley maneuver)
Description: Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
Study NCT00000359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semont maneuver
Description: Sidelying maneuver, flip over 180 deg, sit up.
Study NCT00000359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brandt-Daroff exercises
Description: Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
Study NCT00000359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular habituation exercises
Description: Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
Study NCT00000359 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ShamManeuver
Description: Passive movement of the head
Study NCT05815381 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy
Description: se arm/group descriptions
Study NCT02793947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Study NCT02793947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Study NCT02793947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Study NCT02793947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride solution
Description: 36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
Study NCT02096276 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Initial and follow-up data will be collected using questionnaires.
Study NCT00551395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: selective laser trabeculoplasty - early completion
Description: 180 degrees of laser on day 1 and other 180 degrees on day 2.
Study NCT00551395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty - late completion
Description: 180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
Study NCT01288365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training program for 3 months (two times a week).
Study NCT01302795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Monoclonal antibody inhibiting interleukin 1 beta
Study NCT03430908 — intervention group
Intervention type: OTHER
Intervention: Blind Gastric Tube Placement
Description: The provider will be blinded to the ultrasound imaging throughout the entire insertion. This blind insertion process is the standard of care currently practiced at MSKCC. After the provider verbalizes that they have completed the insertion the investigators will stop the ultrasound imaging and complete the data form. No information will be given to the provider about the location of the gastric tube as to not deviate from the standard of care. The only time that information will be provided to the practitioner inserting the tube will be if the tube is positioned in any of the following positions that are thought to be potentially injurious if unrecognized. These positions include intrapulmonary, cranial, nasal or oral pharyngeal placements and diverticular or hiatal hernia sac coiling and remain unrecognized by the practitioner. These are considered positions that have the potential for injury and therefore will be divulged to prevent ensuing injury.
Study NCT00683488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Focus group using and collecting feedback on the CBT/CM intervention.
Study NCT00683488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First Intervention Trial
Description: Intervention will comprise of approximately 15 weekly sessions.~* Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.~* Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.~* Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility.
Study NCT00683488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Trial 2
Description: Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
Study NCT04156243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CARvac T cells
Description: CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study NCT03738163 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Epaderm Cream
Description: The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
Study NCT00635934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-MAV™ disc
Description: The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
Study NCT03300050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cH8/1N1 LAIV
Description: Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA) with the H8 head and H1 stalk and neuraminidase (NA) subtype 1 (N1) (cH8/1N1):~HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1) containing the backbone of the cold-adapted/temperature sensitive of the Russian LAIV A/Leningrad/134/17/1957 (Len17 IDCDCRG46D).~Administered intranasally as drops at a dose of 10⁷·⁵ (plus or minus ⁰·⁵) 50% egg infectious dose (EID50), formulated in a total volume of 0.5 mL sterile saline (0.25 mL per nostril).